GHRP-6 and CJC-1295 with DAC come up in the same conversations so often that they are frequently treated as two routes to the same destination. They are not. The single most useful fact about GHRP-6 vs CJC-1295 with DAC is that the two compounds bind entirely different receptors, and that is exactly why the research literature studies them alongside each other rather than treating one as a substitute for the other. Understanding which receptor each one talks to explains almost everything else: why their time courses differ by orders of magnitude, why one of them has an appetite signal attached and the other does not, and why the phrase "CJC-1295 without DAC" is one of the most persistent misnomers in this corner of the market.

Scope note. Everything below is reference material describing published laboratory and clinical research. GHRP-6 and CJC-1295 are research-use-only (RUO) compounds. Neither has an approved indication in any jurisdiction. Nothing here is a protocol, a dose, or guidance for use in a person, the sections describe what published studies did, in which species, and what they measured.

GHRP-6 vs CJC-1295 with DAC: the short version

  • GHRP-6 is a synthetic hexapeptide that acts as an agonist at the growth hormone secretagogue receptor (GHS-R1a), the ghrelin receptor. It is cleared in minutes.
  • CJC-1295 with DAC is an analogue of GHRH built on the GRF(1-29) scaffold, acting at the GHRH receptor. Its albumin-binding Drug Affinity Complex stretches its half-life from minutes to days.
  • They are two different keys for two different locks on the same pituitary cell. That is the entire basis for the combination studies described further down.

Two receptors, one axis

Growth hormone release from the anterior pituitary somatotroph is not controlled by a single switch. At minimum, three inputs converge on that cell: GHRH (stimulatory), somatostatin (inhibitory), and ghrelin acting via GHS-R1a (stimulatory, and modulatory over the first two). The interplay between these inputs, not any one of them alone, is what generates the pulsatile pattern that characterises growth hormone secretion in every mammal studied [12].

The GHRH receptor

The GHRH receptor was cloned from rat pituitary in 1992 and is a class B G-protein-coupled receptor expressed with striking tissue specificity on somatotrophs [7]. It couples through Gs, so an agonist raises intracellular cAMP, activates protein kinase A, and drives both the release of stored growth hormone and the transcription of new hormone. This is the classical, "top-down" hypothalamic route: the physiological signal that tells the pituitary to fire.

The catch is durability. Native GHRH is destroyed almost immediately in plasma. Frohman and colleagues showed that dipeptidyl peptidase IV (DPP-4) cleaves human GHRH between residues 2 and 3, removing the N-terminal dipeptide and yielding GHRH(3-44), a fragment that is biologically inactive at the receptor [8]. Because the N-terminus is exactly the part of the molecule the receptor needs, this single cut is enough to switch the signal off. Any GHRH-based molecule intended to last must solve this problem first.

The ghrelin receptor (GHS-R1a)

The second receptor arrived in the literature backwards, and the story is worth knowing because it explains what GHRP-6 actually is. Synthetic peptides that released growth hormone were discovered before anyone knew what they bound. In 1996 Howard and colleagues cloned the receptor these compounds were acting on, a G-protein-coupled receptor in pituitary and hypothalamus, distinct from the GHRH receptor, which they showed functions in growth hormone release [1]. It signals through Gq/11 and the phospholipase C / IP3 / calcium pathway, a different second messenger entirely from the GHRH receptor's cAMP.

At that point it was an orphan receptor: a lock with a synthetic key and no known natural one. The natural ligand was identified three years later, when Kojima and colleagues purified ghrelin from stomach, a 28-amino-acid peptide carrying an unusual n-octanoyl modification on Ser3, without which it does not activate the receptor [2]. So GHS-R1a is properly the ghrelin receptor, and GHRP-6 is a synthetic agonist that got there first.

GHRP-6: a hexapeptide that predates its own receptor

GHRP-6 is a six-residue peptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, developed in the lineage of work by Bowers and colleagues on small peptides that release growth hormone through a mechanism clearly separable from GHRH [3]. Two design features stand out. The D-amino acids (D-Trp at position 2, D-Phe at position 5) are not incidental, non-natural stereochemistry is a standard way to blunt recognition by proteases that evolved against L-peptides. The C-terminal amide likewise removes a free carboxylate that carboxypeptidases would attack.

Even so, GHRP-6 is a short-acting molecule: its action in the published work is measured over minutes, not hours, and certainly not days. This is the fundamental asymmetry in any GHRP-6 vs CJC-1295 with DAC comparison. The class as a whole, the synthetic secretagogues acting at GHS-R1a, was reviewed in detail by Smith and colleagues, who framed these compounds as peptidomimetic regulators of a distinct, GHRH-independent arm of growth hormone control [4].

The appetite signal

Because GHRP-6 activates the ghrelin receptor, it engages a pathway that is not only about growth hormone. Ghrelin's other well-documented role is orexigenic. Wren and colleagues showed that central administration of ghrelin stimulates food intake in rats, in addition to releasing growth hormone [5], establishing GHS-R1a as a node where the somatotropic and appetite systems overlap.

That effect is not confined to rodents or to ghrelin itself. Laferrère and colleagues infused GHRP-2, a synthetic secretagogue at the same receptor, in healthy men and reported an increase in food intake at a subsequent meal, mirroring what ghrelin does [6]. This is worth stating precisely rather than loosely: the strongest human feeding data in this class come from GHRP-2, not GHRP-6, and the honest formulation is that appetite stimulation is a receptor-level property of GHS-R1a agonism that GHRP-6 shares by virtue of binding the same target. CJC-1295 acts at the GHRH receptor instead, and no comparable appetite pathway has been described for it, consistent with a receptor whose expression is largely pituitary-restricted [7].

CJC-1295 with DAC: engineering a GHRH analogue to last

CJC-1295 is a solution to the Frohman problem [8], built in two stages.

Stage one: four substitutions on GRF(1-29)

The scaffold is GRF(1-29), the first 29 residues of GHRH, long known to retain full agonist activity at the receptor, so the remaining residues of the native 44-mer are dispensable. Onto that scaffold, four substitutions were made, each targeting a specific chemical liability [9]:

  • D-Ala at position 2, the direct answer to DPP-4. The enzyme cleaves after residue 2; inverting the stereochemistry there defeats recognition.
  • Gln at position 8, replaces an asparagine prone to deamidation, a slow chemical degradation route.
  • Ala at position 15, a glycine-to-alanine change associated with improved bioactivity.
  • Leu at position 27, replaces a methionine, the residue most vulnerable to oxidation.

Three of the four are stability fixes rather than potency fixes. This tetrasubstituted GRF(1-29) analogue is a genuinely more stable molecule than native GHRH, but robustness against enzymes and oxidation does not fix renal clearance. A peptide of this size is small enough to be filtered out of circulation quickly regardless of how protease-resistant it is. Chemistry alone buys resistance to degradation, not a long stay in circulation.

Stage two: the Drug Affinity Complex

The DAC is the part that changes the pharmacokinetics by orders of magnitude, and its mechanism is more elegant than "it makes the molecule bigger". A maleimidopropionyl group is attached at a Lys30 extension on the peptide. Maleimide chemistry is thiol-selective: after injection, the maleimide reacts with the free cysteine thiol at position 34 of serum albumin, the one reduced, accessible cysteine on the most abundant protein in plasma, forming a covalent bioconjugate in vivo [9].

Note what that means. The conjugation is not a manufacturing step performed in advance; the injected molecule is a reagent that assembles itself onto a carrier already circulating in the subject. Albumin has a half-life measured in weeks, so the peptide inherits a carrier that recycles rather than clears. Jetté and colleagues showed that GRF(1-29)-albumin bioconjugates still activate the GRF receptor on the anterior pituitary in rats, the payload stays functional while tethered, and identified CJC-1295 as the long-lasting analogue from that series [9].

The human pharmacokinetics are reported consistently, though from small early-phase numbers. Teichman and colleagues gave single doses to healthy adults and reported a terminal half-life of roughly 5.8 to 8.1 days, with growth hormone elevated approximately 2- to 10-fold for about six days and IGF-1 elevated approximately 1.5- to 3-fold for nine to eleven days [10]. Minutes to days, from one chemical modification.

CJC-1295 with DAC vs "without DAC": the distinction worth getting right

This is the most common point of confusion in the entire topic, and it is worth owning plainly.

In the published literature, CJC-1295 is the DAC conjugate. The compound Jetté and colleagues named CJC-1295 is the tetrasubstituted GRF(1-29) analogue bearing the albumin-binding Drug Affinity Complex [9]. The DAC is not an optional accessory bolted onto CJC-1295, it is a defining part of what the name refers to. Strictly, "CJC-1295 with DAC" is a redundancy.

What is sold and discussed as "CJC-1295 without DAC" is a different molecule: the tetrasubstituted GRF(1-29) analogue on its own, more accurately called modified GRF(1-29) or mod GRF 1-29. It keeps the four substitutions, so it keeps the DPP-4 resistance, but with no maleimide, there is no albumin conjugation, no carrier, and no multi-day exposure. It is the short-acting, non-DAC member of the pair; the days-long profile documented by Teichman [10] belongs exclusively to the DAC-bearing molecule.

The practical consequence for reading the literature: a paper on CJC-1295 is a paper on the DAC conjugate, and its pharmacokinetics do not transfer to mod GRF(1-29). Anyone comparing GHRP-6 vs CJC-1295 with DAC using half-life figures scraped from a "without DAC" product listing is comparing three compounds while believing they are comparing two.

Why the literature studies the two classes together

Here the two-receptor point pays off. Because GHRP-6 and GHRH analogues act through separate receptors and separate second-messenger systems, calcium versus cAMP, their effects are not merely additive when combined. Bowers and colleagues documented that GHRP and GHRH act synergistically on growth hormone release: co-administration produces a response substantially greater than the sum of each given alone [3].

Synergy of that kind is a mechanistic fingerprint. Two orthosteric agonists competing for the same binding site on one receptor cannot be synergistic, at best they are additive, and past receptor saturation the second one contributes nothing. A greater-than-additive response is evidence that two signals converge on the same cell through independent routes. Which routes, exactly, is a separate question, and one the primary source leaves open. Bowers and colleagues specifically excluded the obvious candidates: the GHRP + GHRH synergistic response was not explained by inhibition of somatostatin (SRIF) release, nor by stimulation of endogenous GHRH, and an alternative mechanism was proposed rather than identified [3]. The GHRH arm supplies the primary stimulatory drive and hormone synthesis, and somatostatin's oscillating inhibition is a genuine limb of the axis [4][12], but attributing this particular synergy to GHS-R1a agonism releasing the somatostatin brake goes further than the source supports. The mechanism remains unresolved. Studying them together is not a matter of stacking for a bigger number, it is how the independence of the two pathways was demonstrated in the first place.

Pulsatility: the variable a days-long agonist puts under pressure

Growth hormone is not secreted at a steady level. It is released in discrete bursts, and the pattern itself, amplitude, frequency, the troughs in between, is a regulated feature of the axis rather than noise on top of an average [12]. This raises an obvious question for a molecule with a half-life approaching a week: does continuous receptor stimulation flatten the pulses into a plateau?

It was tested directly. Ionescu and Frohman examined growth hormone secretion during continuous stimulation by CJC-1295 and reported that pulsatile secretion persists: mean growth hormone levels rose substantially, but the pulsatile architecture was retained rather than abolished [11]. The mechanistic reading is that pulsatility is not generated by the GHRH signal switching on and off, somatostatin's oscillating inhibitory input continues to gate the somatotroph even when GHRH-receptor drive is constant. The result is a raised baseline with pulses still riding on it.

This is a genuinely informative finding, and also a bounded one: it describes what happened over the studied interval in the studied subjects. It is not a general guarantee that any duration or magnitude of continuous GHRH-receptor stimulation leaves the architecture of the axis intact.

Limits of the evidence

An honest accounting matters more here than in most topics, because the gap between what is known and what is claimed is wide.

  • No approved indication. Neither GHRP-6 nor CJC-1295 is an approved medicine anywhere. They are laboratory reagents. CJC-1295's clinical development did not carry through to approval, and the human data that exist are early-phase.
  • The human dataset is small and short. The key human pharmacokinetic work on CJC-1295 involved small numbers of healthy adults over limited follow-up [10][11]. Small early-phase studies characterise a hormone response; they do not establish long-term safety, and they are not designed to.
  • The mechanistic core is rodent-dominant. The receptor pharmacology, the synergy characterisation, and the albumin-conjugate validation rest substantially on rat and cell-based work [1][3][9]. Species differences in this axis are real.
  • Human GHRP-6-specific feeding data are thin. As noted above, the human feeding evidence in this class comes from GHRP-2 [6]; extending it to GHRP-6 is a receptor-level inference, not a direct finding.
  • Raising a hormone is not the same as an outcome. Elevated growth hormone and IGF-1 are biomarkers. Studies measuring hormone concentrations report exactly that, they do not demonstrate any downstream clinical benefit, and none should be inferred from them.
  • The literature is old. Much of the foundational work dates from the 1990s and 2000s. Little has been added since, which is itself informative: these compounds were not carried forward.

Reference and handling notes

Both compounds are supplied as lyophilised powder, which is a stability decision rather than a packaging preference, peptides in solution degrade far faster than in the dry state. Choice of diluent depends on the assay: in vitro and cell-culture work generally uses sterile water, buffered saline such as PBS, or dilute acetic acid for peptides that need it, with preservative-free options preferred wherever cells are involved. Bacteriostatic water is a different thing: a benzyl-alcohol-preserved diluent formulated for multi-dose human injectables. Our reference monograph on bacteriostatic water covers where that distinction matters. Specifications and analytical documentation for our GHRP-6 reference material are listed on the product page, and every batch we ship carries third-party purity and identity testing, for compounds like these: provenance and analytics are the whole question, not the label.

Longeva supplies these materials strictly for research use. We do not provide dosing protocols or administration guidance, and nothing on this page should be read as either.

The full list of sources with links, is in the monographs: GHRP-6, CJC-1295 with DAC.